Hospira Reinforces Importance of Clinical Surveillance Technology in Line With World Health Day Focus on Antimicrobial Resistanc

-- Supports WHO initiative through application of advanced technology to help combat the antimicrobial resistance threat --

LAKE FOREST, Ill., April 7, 2011 /PRNewswire/ -- As part of World Health Day 2011, the World Health Organization (WHO) is calling on policy makers, providers, the public and the healthcare industry to take action to combat the serious health threat of antimicrobial resistance (AMR).  Aligned with these efforts, Hospira (NYSE: HSP) is focusing on the growing importance of clinical surveillance systems to help reduce AMR by helping healthcare providers optimize antibiotic therapy and provide the "right drug for the right bug."

Antimicrobial agents, used to treat infections, are one of the most important advances in medicine, alleviating suffering from infectious diseases and saving countless lives over the past 70 years.(1) According to WHO, the world is at risk of losing this critical arsenal of medicines due to the overuse and misuse of antimicrobials, as well as poor infection-control practices, resulting in the spread of healthcare-associated infections (HAIs). These challenges increase antimicrobial use and resistance, and have been linked to patient morbidity and mortality. According to WHO reports, at any given time, approximately 1.7 million people have an HAI, an estimated 60 percent of which are caused by a drug-resistant bacteria.(2)(3)

In the United States, antimicrobial drug resistance is estimated to deliver an incremental cost of $16.6 billion to $26 billion annually.(4) As a result, hospitals are taking steps to address the problem, utilizing clinical surveillance systems to help them identify and prevent HAIs and combat AMR through real-time decision support focused on improving antibiotic use.

Clinical surveillance systems play a key role in the antimicrobial stewardship program at Henry Ford Hospital in Detroit, part of the Henry Ford Health System, helping to replace inefficient, labor-intensive manual methods of antibiotic and antimicrobial monitoring.

"Henry Ford Hospital deployed the TheraDoc™ clinical surveillance platform to improve the efficiency of the antimicrobial stewardship program," said Ed Szandzik, R.Ph., M.B.A., director of pharmacy, Henry Ford Health System. "The technology has helped prevent the overuse and misuse of antibiotics. Our stewardship program has been able to reduce antimicrobial use by 20 percent and help reverse the trend on C. difficile rates (which are currently below the Centers for Disease Control benchmark) through enhanced guidelines, policies, procedures and electronic monitoring."

Policy makers are also taking steps to address the growing problems of HAIs and the potential for associated antimicrobial resistance. For example, U.S. Rep. Jim Matheson (D-Utah) has been a leader in this area with his legislation: "Strategies to Address Antimicrobial Resistance Act" (STAAR Act), which supports many of the WHO AMR policies. In addition, several states have enacted legislation to require statewide reporting of HAIs. Many states now require hospitals to electronically report HAIs through the National Healthcare Safety Network (NHSN).

Reporting HAIs alone, however, is often not enough. Combating AMR requires a comprehensive approach of reducing HAIs through surveillance and the appropriate use of antibiotics. This comprehensive approach is already achieving results in some states. After implementing a mandatory reporting program for HAIs, which also requires use of electronic clinical surveillance systems to track and report infections, the Pennsylvania Department of Health reported a 12.5 percent reduction in HAIs in the state's acute-care hospitals in 2009.(5)

"Reducing HAIs is critical in the fight against antimicrobial resistance, as poor infection prevention and control can increase the spread of antibiotic-resistant infections," said France Pitera, vice president, Clinical Information Technology, Hospira. "Hospitalized patients can be reservoirs for resistant microorganisms, and patients who are carriers of resistant microorganisms can spread infections to other patients. For this reason, electronic clinical surveillance systems that leverage real-time data exchange to help hospitals address both problems -- HAIs and antimicrobial resistance -- are crucial."

About the TheraDoc Clinical Surveillance Platform

TheraDoc systems are actively used in more than 300 U.S. hospitals, making critical patient information and medical knowledge readily available to help clinicians intervene quickly, prescribe appropriately and improve the quality of patient care, as well as facilitate reporting of HAIs via the NHSN. The patented TheraDoc clinical surveillance platform is the engine that powers several knowledge modules, including the Infection Control Assistant™, Antibiotic Assistant™, ADE Assistant™, Clinical Alerts Assistant™ and Anticoagulation Assistant™. For more information about TheraDoc, visit http://www.theradoc.com or call (801) 415-4400.  

About Hospira

Hospira, Inc., is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™.  As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost, and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees.  Learn more at http://www.hospira.com.

(1) Centers for Disease Control and Prevention. July 22, 2010. About Antimicrobial Resistance: A Brief Overview, http://www.cdc.gov/drugresistance/about.html, Accessed April 6, 2011  

(2) U.S. Department of Health & Human Services. (n.d.) Healthcare-Associated Infections, http://www.hhs.gov/ash/initiatives/hai/, Accessed March 29, 2011

(3) World Health Organization. Medicines are losing their effectiveness, 1999, http://www.who.int/infectious-disease-report/pages/ch12text.html, Accessed April 6, 2011

(4) Center for Global Development. The Race Against Drug Resistance, 2010, http://www.cgdev.org/files/1424207_file_CGD_DRWG_FINAL.pdf, Accessed April 6, 2011

(5) Ledue, Chelsey. "HAI report highlights improvement at Pennsylvania hospitals." Healthcare Finance News, June 28, 2010,  http://www.healthcarefinancenews.com/news/hai-report-highlights-improvement-pennsylvania-hospitals, Accessed April 16, 2011



SOURCE Hospira

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.